McKesson (NYSE:MCK) Price Target Raised to $1,020.00

McKesson (NYSE:MCK) had its price objective increased by Mizuho from $905.00 to $1,020.00 in a report issued on Tuesday, Marketbeat reports. The firm currently has a neutral rating on the stock.

A number of other brokerages have also weighed in on MCK. Wells Fargo & Company increased their target price on McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 11th. Robert W. Baird set a $1,015.00 price target on McKesson in a research note on Thursday, August 6th. Morgan Stanley set a $977.00 price target on McKesson in a research note on Tuesday, October 6th. UBS Group upped their price objective on McKesson from $1,080.00 to $1,200.00 and gave the company a “buy” rating in a report on Friday, October 16th. Finally, Argus increased their price objective on McKesson from $850.00 to $970.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $997.12.

McKesson Stock Down 0.5%

McKesson stock opened at $1,010.85 on Tuesday. The stock has a market cap of $117.86 billion, a P/E ratio of 24.88, a P/E/G ratio of 2.02 and a beta of 0.30. McKesson has a twelve month low of $723.68 and a twelve month high of $1,030.27. The company’s 50-day moving average price is $908.70 and its two-hundred day moving average price is $841.27.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.56 by $0.37. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The firm had revenue of $105.38 billion during the quarter, compared to the consensus estimate of $103.88 billion. During the same period last year, the business posted $8.26 earnings per share. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Equities analysts anticipate that McKesson will post 44.71 earnings per share for the current fiscal year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is currently 10.06%.

Insider Transactions at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the sale, the chief accounting officer directly owned 521 shares in the company, valued at approximately $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 800 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $995.80, for a total value of $796,640.00. Following the sale, the executive vice president directly owned 5,423 shares in the company, valued at $5,400,223.40. This represents a 12.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,212 shares of company stock valued at $1,164,182. 0.06% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On McKesson

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Secure Asset Management LLC lifted its position in McKesson by 484.8% during the second quarter. Secure Asset Management LLC now owns 2,123 shares of the company’s stock worth $1,604,000 after purchasing an additional 1,760 shares during the period. Royal London Asset Management Ltd. grew its stake in McKesson by 1.1% during the second quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company’s stock worth $84,809,000 after buying an additional 1,216 shares in the last quarter. Benchmark Investment Advisors LLC acquired a new stake in McKesson during the second quarter worth about $441,000. Summit Global Investments acquired a new stake in McKesson during the second quarter worth about $1,159,000. Finally, One Wealth Advisors LLC bought a new position in McKesson in the 2nd quarter valued at about $1,494,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Mizuho raised its price target for McKesson to $1,020, implying modest additional upside from recent trading levels. The upgrade follows the stock reaching a new one-year high and could support investor confidence. Mizuho raises McKesson price target
• Positive Sentiment: A recent analysis argues that artificial-intelligence initiatives and a potential FDA overhaul could become larger growth drivers for McKesson in 2027, potentially outweighing current regulatory headwinds. McKesson AI and FDA outlook
• Neutral Sentiment: McKesson declared a quarterly dividend of $0.94 per share, payable January 4, 2027, to shareholders of record December 1. The annualized payout is $3.76, representing a relatively low yield of about 0.4%, so the announcement is primarily a signal of continued shareholder returns rather than a major income catalyst. McKesson declares quarterly dividend
• Neutral Sentiment: Investor attention remains elevated after McKesson’s strong long-term performance and recent analyst upgrade, but elevated valuation and the stock’s proximity to its 52-week high may limit near-term upside. McKesson reaches one-year high
• Negative Sentiment: An insider, Francisco Fraga, reportedly sold 800 McKesson shares. The transaction is not necessarily a fundamental warning, but insider selling can weigh modestly on sentiment. McKesson insider share sale
• Negative Sentiment: Coverage of a McKesson-related security incident highlights potential cybersecurity and operational risks, which could add to investor concerns alongside regulatory uncertainty. McKesson security incident analysis

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.